Evidence map›Paper›PMID 34315881›Full record

ArticleNature communications2021

Pulmonary fibrosis distal airway epithelia are dynamically and structurally dysfunctional.

Ian T Stancil, Jacob E Michalski, Duncan Davis-Hall, Hong Wei Chu, Jin-Ah Park, Chelsea M Magin, Ivana V Yang, Bradford J Smith, Evgenia Dobrinskikh, David A Schwartz

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 107 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. IPF AT2 cells are stuck in transition and biophysically dysfunctional.bioRxiv : the preprint server for biology · 2026
    Article
  11. Mechanobiology and Resolution of Lung Fibrosis.Annual review of physiology · 2026
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Pulmonary Fibrosis-Focusing on the Future: Aspen Lung Conference 2024 Summary.American journal of respiratory cell and molecular biology · 2025
    Article
  19. Hesperetin Alleviates Bleomycin-Induced Pulmonary Fibrosis by Modulating Cellular Senescence and Promoting Impaired Autophagy in a CISD2-Dependent Manner.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ian T StancilDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0002-0215-3428
Jacob E MichalskiDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Duncan Davis-HallDepartment of Bioengineering, University of Colorado Denver | Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0003-1280-8018
Hong Wei ChuDepartment of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Jin-Ah ParkHarvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-8930-9287
Chelsea M MaginDepartment of Bioengineering, University of Colorado Denver | Anschutz Medical Campus, Aurora, CO, USA.
Ivana V YangDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Bradford J SmithDepartment of Bioengineering, University of Colorado Denver | Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0002-1583-6762
Evgenia DobrinskikhDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
David A SchwartzDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. David.Schwartz@cuanschutz.edu.ORCID 0000-0001-6743-8443
University of Colorado Anschutz Medical Campus · USHarvard University · USNational Jewish Health · US

Funding

Translational Research Support CoreP30ES000002 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI SUSAN A KORRICK · 1985 to 2026
$44.6M
Mechanisms of Familial Pulmonary FibrosisP01HL092870 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LOYD, JAMES E · 2010 to 2020
$21.6M
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)R01HL097163 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI FINGERLIN, TASHA E., SCHWARTZ, DAVID ALBERT · 2009 to 2018
$16.4M
University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI PETER J DEMPSEY · 2020 to 2026
$10.8M
ZEBRAFISH TRANSGENIC CORE - ROCKY MOUNTAIN NEUROLOGICAL DISORDERS CORE CENTERP30NS048154 · NINDS · UNIVERSITY OF COLORADO DENVER · PI RIBERA, ANGELES BADELL · 2004 to 2020
$10.1M
University of Colorado Aging Training GrantT32AG000279 · NIA · UNIVERSITY OF COLORADO DENVER · PI Kerrie Moreau · 2001 to 2026
$10.1M
Cardiovascular Biomechanics and Imaging in Down SyndromeT32HL072738 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SHANDAS, ROBIN · 2003 to 2025
$4.9M
MUC5B, a novel therapeutic target for Idiopathic Pulmonary Fibrosis (IPF)UH3HL123442 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2016 to 2018
$4.8M
Preclinical Pulmonary Fibrosis, an opportune rare disease cohortUH3HL151865 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2022 to 2025
$4.3M
Genes and Transcripts that Interact with MUC5B in Pulmonary FibrosisR01HL149836 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI CLOUTHIER, DAVID E., SCHWARTZ, DAVID ALBERT · 2020 to 2023
$3.0M
Hybrid Hydrogel Biomaterials Comprising Clickable Decellularized Extracellular Matrix for Engineering Dynamic 3D Models of FibrosisR01HL153096 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI MAGIN, CHELSEA M · 2020 to 2024
$2.6M
Physics of bronchial epithelial unjammingR01HL148152 · NHLBI · HARVARD SCHOOL OF PUBLIC HEALTH · PI FREDBERG, JEFFREY J, PARK, JIN-AH · 2019 to 2022
$2.2M
BLRD VA I01 BX005295NHLBI NIH HHS F31 HL151122NHLBI NIH HHS P01 HL092870NHLBI NIH HHS R01 HL097163NHLBI NIH HHS R01 HL148152NHLBI NIH HHS R01 HL149836NHLBI NIH HHS R01 HL153096NHLBI NIH HHS T32 HL072738NHLBI NIH HHS UH3 HL123442NHLBI NIH HHS UH3 HL151865NIA NIH HHS T32 AG000279NIDDK NIH HHS P30 DK116073NIEHS NIH HHS P30 ES000002NINDS NIH HHS P30 NS048154
6 · The paper itself

Abstract

The airway epithelium serves as the interface between the host and external environment. In many chronic lung diseases, the airway is the site of substantial remodeling after injury. While, idiopathic pulmonary fibrosis (IPF) has traditionally been considered a disease of the alveolus and lung matrix, the dominant environmental (cigarette smoking) and genetic (gain of function MUC5B promoter variant) risk factor primarily affect the distal airway epithelium. Moreover, airway-specific pathogenic features of IPF include bronchiolization of the distal airspace with abnormal airway cell-types and honeycomb cystic terminal airway-like structures with concurrent loss of terminal bronchioles in regions of minimal fibrosis. However, the pathogenic role of the airway epithelium in IPF is unknown. Combining biophysical, genetic, and signaling analyses of primary airway epithelial cells, we demonstrate that healthy and IPF airway epithelia are biophysically distinct, identifying pathologic activation of the ERBB-YAP axis as a specific and modifiable driver of prolongation of the unjammed-to-jammed transition in IPF epithelia. Furthermore, we demonstrate that this biophysical state and signaling axis correlates with epithelial-driven activation of the underlying mesenchyme. Our data illustrate the active mechanisms regulating airway epithelial-driven fibrosis and identify targets to modulate disease progression.

Indexed as

Adaptor Proteins, Signal TransducingAmphiregulinBiophysical PhenomenaEpitheliumErbB ReceptorsFibroblastsGenetic Predisposition to DiseaseHumansIdiopathic Pulmonary FibrosisKeratin-5LungMucin-5BQuinazolinesRisk FactorsRNA, MessengerSignal TransductionAdaptor Proteins, Signal TransducingAmphiregulinAREG protein, humanErbB ReceptorsKeratin-5Mucin-5BQuinazolinesRNA, MessengerRTKI cpdTranscription FactorsTyrphostinsVerteporfinYAP1 protein, humanYAP-Signaling Proteins

Identifiers

PMID34315881
PMCPMC8316442
OpenAlexW3185578829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.